Several preclinical and clinical trials have demonstrated that antiangiogenic therapies can inhibit NF2-associated VS tumor growth and postpone the related hearing loss (Wong et al., 2010; Gao et al., 2015; Killeen et al., 2019; Renzi et al., 2020). Here, NF2 is linked to neoplasm.